Alector, Inc.

Ladies and gentlemen, and welcome to the Alcator Mid-Year 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. As a reminder, this conference call is being recorded. I would now like to turn the call over to Katie Hogan, Senior Director of Corporate Communication and Investor Relations. Please go ahead.

Thank you, Operator, and good afternoon, everyone. Earlier this afternoon, we released our financial results for the second quarter of 2023. The press release is available on our website at www.elector.com. And our 10-Q is filed with the Securities and Exchange Commission this afternoon. Joining me on the call today are Dr. Arnon Rosenthal, co-founder and CEO, Dr. Sarah Kankari Mitra, President and Head of Research and Development, Dr. Gary Romano, Chief Medical Officer, and Dr. Mark Grasso, Chief Financial Officer. After our formal remarks, we'll open the call for Q&A. I'd like to note that during this call, we will be making a number of forward-looking statements. Please take a moment to review our slide in the webcast, which contains our forward-looking statement disclosure, and we also encourage you to review our FPC filings for more information. I would now like to turn the call over to Arnon Rosenthal, Chief Executive Officer. Arnon?

Thank you, Katie, and good afternoon, everyone. We appreciate you joining our conference call today. I'll start by highlighting Elector's key initiatives during the first half of 2023. Next, Sarah will share the progress we believe we have achieved with our immunoneurology research. Then, I invite Gary to discuss the late-stage clinical program. Afterwards, Mark will provide an update on our financial results and milestones. Today, Alekto is a late-stage clinical biotechnology company with an advanced pipeline that includes novel first-in-class clinical programs. We also have world-class partnerships in which we retain significant rights as well as innovative research and technology portfolios. Regarding our TRUMP2 program, we provide more details about our Invoke2 Phase 2 clinical trial with AL002. The tribe is approaching full enrollment, and nearly all eligible participants are rolling over into the long-term extension portion of the study. We're also looking forward to sharing key highlights from the 002 program we presented at the Alzheimer's Association International Conference, or AAIC, in July. As presented at AAIC, in a mouse model of Alzheimer's disease, our antibody AL002 was shown to reduce total tau in the serum, which is a biomarker for normal repair, as well as to increase the ratio of A-beta 42 to 40, which may affect remodeling of amyloid plaque. Further, we are encouraged that AL002 was well tolerated in our Phase I trial with healthy volunteers. The fact that we are seeing what appears to be incidences of ARIA in INVOX2 participants associated with EPOE4 status we believe is interesting and suggest biological activity. With enrollment invoked to nearly complete, we are advancing closer to potential meaningful data readout. We will also share with you the outcome of our recent productive agency interactions with the FDA and EMA on our InFRONT3, phase three pivotal trial evaluating latiluzumab in frontotemporal dementia. The enrollment in InFRONT3 is also nearly complete. We will also provide a brief update on our InFRONT2 open-label phase two clinical trial in frontotemporal dementia with D9072 mutation. With that, I will turn over to Sarah to highlight the progress we have achieved with our immunoneurology research.